Dyne Historical Financial Ratios
| DYN Stock | USD 30.96 0.54 1.71% |
Dyne Therapeutics is recently reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 9.13 or Days Sales Outstanding of 316 will help investors to properly organize and evaluate Dyne Therapeutics financial condition quickly.
Dyne |
About Dyne Financial Ratios Analysis
Dyne TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Dyne Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Dyne financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Dyne Therapeutics history.
Dyne Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Dyne Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Dyne Therapeutics sales, a figure that is much harder to manipulate than other Dyne Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Dyne Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Dyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.At this time, Dyne Therapeutics' PTB Ratio is very stable compared to the past year. As of the 12th of June 2024, PB Ratio is likely to grow to 9.13, while Price To Sales Ratio is likely to drop 6.54.
| 2023 | 2024 (projected) | Payables Turnover | 0.11 | 0.1 | Days Of Inventory On Hand | 49.86 | 48.73 |
Dyne Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Dyne Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dyne Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 77.34 | 0.88 | 1.64 | 2.39 | 8.7 | 9.13 | |
| Book Value Per Share | 0.31 | 23.78 | 7.23 | 4.86 | 1.53 | 1.45 | |
| Free Cash Flow Yield | (0.0124) | (0.16) | (0.2) | (0.26) | (0.24) | (0.23) | |
| Invested Capital | 4.44 | (0.69) | 0.0886 | 0.12 | 0.3 | 0.29 | |
| Operating Cash Flow Per Share | (0.26) | (3.23) | (2.35) | (2.96) | (3.15) | (2.99) | |
| Capex To Depreciation | (6.08) | (1.66) | (3.33) | (1.82) | (0.3) | (0.31) | |
| Pb Ratio | 77.34 | 0.88 | 1.64 | 2.39 | 8.7 | 9.13 | |
| Free Cash Flow Per Share | (0.3) | (3.31) | (2.42) | (3.02) | (3.16) | (3.01) | |
| Roic | (0.9) | (0.17) | (0.37) | (0.59) | (2.04) | (1.94) | |
| Net Income Per Share | (0.3) | (4.08) | (2.93) | (3.18) | (3.95) | (4.15) | |
| Payables Turnover | 0.22 | 0.2 | 0.27 | 0.64 | 0.11 | 0.1 | |
| Cash Per Share | 0.32 | 23.99 | 7.4 | 4.93 | 2.06 | 1.96 | |
| Pocfratio | (91.74) | (6.5) | (5.06) | (3.92) | (4.22) | (4.01) | |
| Capex To Operating Cash Flow | 0.14 | 0.025 | 0.0303 | 0.02 | 0.003874 | 0.003681 | |
| Pfcf Ratio | (80.53) | (6.34) | (4.91) | (3.84) | (4.2) | (3.99) | |
| Days Payables Outstanding | 1.7K | 1.8K | 1.4K | 573.85 | 3.4K | 3.6K | |
| Income Quality | 7.7 | 0.87 | 0.8 | 0.78 | 0.91 | 0.71 | |
| Roe | (0.96) | (0.17) | (0.41) | (0.65) | (2.58) | (2.46) | |
| Ev To Operating Cash Flow | (90.5) | (0.0315) | (3.65) | (3.0) | (3.72) | (3.53) | |
| Pe Ratio | (80.2) | (5.15) | (4.05) | (3.65) | (3.36) | (3.2) | |
| Return On Tangible Assets | (0.82) | (0.17) | (0.35) | (0.54) | (1.43) | (1.36) | |
| Ev To Free Cash Flow | (79.44) | (0.0307) | (3.55) | (2.94) | (3.7) | (3.52) | |
| Earnings Yield | (0.0125) | (0.19) | (0.25) | (0.27) | (0.3) | (0.28) | |
| Net Debt To E B I T D A | 1.0 | 5.13 | 1.13 | 0.83 | 0.39 | 0.37 | |
| Current Ratio | 6.26 | 31.49 | 13.31 | 9.11 | 2.53 | 4.74 | |
| Graham Number | 1.44 | 46.73 | 21.85 | 18.64 | 11.66 | 17.36 | |
| Shareholders Equity Per Share | 0.31 | 23.78 | 7.23 | 4.86 | 1.53 | 1.45 | |
| Debt To Equity | 4.44 | (0.69) | 0.0886 | 0.12 | 0.3 | 0.29 | |
| Capex Per Share | (0.0363) | (0.0806) | (0.0711) | (0.059) | (0.0122) | (0.0128) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Dyne Stock
When determining whether Dyne Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.98) | Return On Assets (0.41) | Return On Equity (0.71) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.